Precigen (Intrexon) Priced, NYSE: PGEN
Developing synthetic biology technologies to improve drugs and food.
Industry: Health Care
First Day Return: +54.6%
PGEN
Developing synthetic biology technologies to improve drugs and food.
| IPO Data | |
|---|---|
| IPO Date | 08/07/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $160 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Germantown, MD, United States |
| Founded | 1998 |
| Employees at IPO | 204 |
| Website www.dna.com | |
IPO News for Precigen (Intrexon)
Precigen (Intrexon) (PGEN) Performance
